STOCK TITAN

Castle Biosciences’ Tobin W. Juvenal sells 3,195 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Castle Biosciences (CSTL) Chief Commercial Officer Tobin W. Juvenal exercised options for 3,195 common shares at $29.50 per share on November 11, 2026, and sold 3,195 shares the same day at a weighted-average $35.07 per share. Sale prices ranged from $35.04 to $35.11. The options were fully vested, and no Rule 10b5-1 plan is reported.

Insider Juvenal Tobin W
Role Chief Commercial Officer
Sold 3,195 shs ($112K)
Approx. gross sale proceeds $112K
Approx. exercise cost $94K
Approx. pre-tax spread $18K
Share of Position Sold 8.9%
Type Security Shares Price Value
Exercise Stock option (right to buy) F2 3,195 $0.00 $0.00
Exercise Common Stock 3,195 $29.50 $94K
Sale Common Stock F1 3,195 $35.07 $112K
Holdings After Transaction: Stock option (right to buy) — 31,805 options (Direct); Common Stock — 32,737 shares (Direct)
Holdings Before and After: Stock option (right to buy), 35,000 to 31,805 options (Direct); Common Stock, 32,737 to 32,737 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
  1. F1. This transaction was executed in multiple trades at prices ranging from $35.04 to $35.11, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. F2. The shares subject to the option are fully vested.
Shares acquired on option exercise 3,195 shares Common shares acquired on November 11, 2026.
Option exercise price $29.50 per share Price for the option exercise on November 11, 2026.
Shares sold 3,195 shares Sale on November 11, 2026.
Weighted-average sale price $35.07 per share Weighted-average price for the sale on November 11, 2026.
Sale price range $35.04 to $35.11 per share Prices across the multiple sale trades on November 11, 2026.
Options remaining after exercise 31,805 options Direct option position following the November 11, 2026 exercise.
weighted-average sale price financial
"the price reported above reflects the weighted-average sale price"
fully vested financial
"the shares subject to the option are fully vested"
stock option financial
"Stock option (right to buy)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CSTL shares did Tobin W. Juvenal sell and at what price?

Tobin W. Juvenal, Castle Biosciences' Chief Commercial Officer, sold 3,195 shares on November 11, 2026, at a weighted-average price of $35.07 per share. The reported trades ranged from $35.04 to $35.11.

How many CSTL options remained after Tobin W. Juvenal's exercise?

31,805 options remained after the exercise, with an expiration date of December 12, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Juvenal Tobin W

(Last)(First)(Middle)
C/O CASTLE BIOSCIENCES, INC.
1500 W. PARKWOOD AVE SUITE 400

(Street)
FRIENDSWOOD TEXAS 77546

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/11/2026M3,195A$29.535,932D
Common Stock11/11/2026S3,195D$35.07(1)32,737D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$29.511/11/2026M3,195 (2)12/12/2029Common Stock3,195$031,805D
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $35.04 to $35.11, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
2. The shares subject to the option are fully vested.
Remarks:
/s/ Frank Stokes, Attorney-in-fact11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading